- Home
- RUBI vs ENVB Comparison
RUBI vs ENVB Comparison
Compare RUBI & ENVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RUBI | ENVB |
|---|---|---|
| Founded | N/A | 1994 |
| Country | Marshall Islands | United States |
| Employees | N/A | N/A |
| Industry | Marine Transportation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.1M | 3.0M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | RUBI | ENVB |
|---|---|---|
| Price | $1.11 | $3.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $120.00 |
| AVG Volume (30 Days) | 807.3K | ★ 1.9M |
| Earning Date | 05-06-2020 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $24,139,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $0.42 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.01 | $3.70 |
| 52 Week High | $200.70 | $96.30 |
Technical Indicators
Market Signals| Indicator | RUBI | ENVB |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 40.00 |
| Support Level | N/A | $4.90 |
| Resistance Level | N/A | $5.34 |
| Average True Range (ATR) | 0.00 | 0.85 |
| MACD | 0.00 | -0.29 |
| Stochastic Oscillator | 0.00 | 0.80 |
Price Performance
Historical ComparisonAbout RUBI Rubico Inc.
Rubico Inc operates as a holding company. It is an eco-conscious international crude oil shipping company. The company's primary business is the ownership and operation of an eco-conscious fleet of tanker vessels designed for enhanced fuel efficiency, reduced greenhouse emissions, and a wide range of environmentally friendly technologies.
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.